---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-081307"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2024-07-22T23:59:59+00:00"
generated_at: "2026-05-31T18:27:19.491529+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cellectar raises $19.4M via warrant exercise; new warrants could add $73.3M

## Summary
- Gross proceeds of ~$19.4M from exercise of Tranche B warrants at reduced price of $2.52/share.
- New Tranche A, B, C warrants could generate up to $73.3M additional gross proceeds if exercised.
- Tranche A warrants ($2.52 exercise) trigger on FDA assigning PDUFA date for iopofosine I 131.
- Tranche B ($4.00) triggers on FDA approval; Tranche C ($5.50) on quarterly revenue >$10M from iopofosine.
- Company expects to file NDA for iopofosine I 131 in Q4 2024, seeking priority review.

## SEC filing metadata
- accession: 0001104659-24-081307
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2024-07-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465924081307/0001104659-24-081307-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465924081307/tm2419897d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-081307
- JSON: https://secwatch.observer/filing/0001104659-24-081307.json
- Plain text: https://secwatch.observer/filing/0001104659-24-081307.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.